Industry News - Health Canada approves laser therapy devices

July 14, 2011
July 13, Solon, OH – Multi Radiance Medical, an international laser therapy company, is pleased to announce that Health Canada has approved the MR4 laser therapy devices for use in Canada.

This approval through the Therapeutic Products Directorate of the Medical Devices Bureau of Health Canada includes console and portable units, emitters and the MR4 LaserStim flagship device which is the world’s most advanced pain relief modality.

The MR4 LaserStim is the only hybrid technology that combines a laser and electrical neuro-stimulation. In addition, the MR4 LaserStim comes with exclusive TARGET technology (Treatment Area Recognition and Guidance Enhanced Technology), which identifies optimal treatment areas. As the handheld LaserStim emitter is moved over the tissue, treatment areas are identified assisting the clinician with the correct dose of highly targeted treatments. 

The effectiveness of laser therapy is backed by over 4000 clinical studies.  The MR4 laser uses 25,000 – 50,000mW of super pulsed power which is greater than most class IV lasers with a higher degree of safety.  This provides accelerated pain relief and healing. 

Max Kanarsky, President of Multi Radiance Medical states, "Over 400,000 Multi Radiance Medical devices have been sold in more than 30 countries providing relief via 300+ treatment protocols.  We are excited to now be able to offer MR4 laser therapy devices to clinicians throughout Canada.”

MR4 lasers are utilized for athletes around the world including players on NHL teams and many NBA and MLB teams. 


For additional information please contact Susan Vetrone at This e-mail address is being protected from spambots. You need JavaScript enabled to view it 440-542-0761 x112



Add comment

Security code

Subscription Centre

New Subscription
Already a Subscriber
Customer Service
View Digital Magazine Renew

Most Popular

We are using cookies to give you the best experience on our website. By continuing to use the site, you agree to the use of cookies. To find out more, read our Privacy Policy.